Esperion Therapeutics Valuation
| ESPR Stock | USD 3.48 0.08 2.35% |
At this time, the firm appears to be undervalued. Esperion Therapeutics shows a prevailing Real Value of $4.09 per share. The current price of the firm is $3.48. Our model computes the value of Esperion Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 239.06 M, profit margin of (0.35) %, and Current Valuation of 1.04 B as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Esperion Therapeutics' valuation include:
Undervalued
Today
Please note that Esperion Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Esperion Therapeutics is based on 3 months time horizon. Increasing Esperion Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Esperion stock is determined by what a typical buyer is willing to pay for full or partial control of Esperion Therapeutics. Since Esperion Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Esperion Stock. However, Esperion Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.48 | Real 4.09 | Target 6.51 | Hype 3.42 |
The intrinsic value of Esperion Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Esperion Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Esperion Therapeutics helps investors to forecast how Esperion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Esperion Therapeutics more accurately as focusing exclusively on Esperion Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Esperion Therapeutics' intrinsic value based on its ongoing forecasts of Esperion Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Esperion Therapeutics' closest peers.
Esperion Therapeutics Cash |
|
Esperion Revenue by Product
Esperion Therapeutics Total Value Analysis
Esperion Therapeutics is currently projected to have valuation of 1.04 B with market capitalization of 827.16 M, debt of 591.21 M, and cash on hands of 185.84 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Esperion Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.04 B | 827.16 M | 591.21 M | 185.84 M |
Esperion Therapeutics Investor Information
About 50.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.54. Esperion Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 11th of June 2013. Based on the key indicators related to Esperion Therapeutics' liquidity, profitability, solvency, and operating efficiency, Esperion Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Esperion Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Esperion Therapeutics has an asset utilization ratio of 96.65 percent. This connotes that the Company is making $0.97 for each dollar of assets. An increasing asset utilization means that Esperion Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Esperion Therapeutics Profitability Analysis
Based on Esperion Therapeutics' profitability indicators, Esperion Therapeutics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Esperion Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2000-03-31 | Previous Quarter -12.7 M | Current Value -31.3 M | Quarterly Volatility 36.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.89 | 0.91 |
|
|
For Esperion Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Esperion Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Esperion Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Esperion Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Esperion Therapeutics over time as well as its relative position and ranking within its peers.
Esperion Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Esperion Therapeutics is estimated to be 0.024175 with future projections ranging from a low of -0.08 to a high of 0.145. Esperion Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.54. Please be aware that the consensus of earnings estimates for Esperion Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Esperion Therapeutics Earnings Estimation Breakdown
The calculation of Esperion Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Esperion Therapeutics is estimated to be 0.024175 with the future projection ranging from a low of -0.08 to a high of 0.145. Please be aware that this consensus of annual earnings estimates for Esperion Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.08 Lowest | Expected EPS | 0.14 Highest |
Esperion Therapeutics Earnings Projection Consensus
Suppose the current estimates of Esperion Therapeutics' value are higher than the current market price of the Esperion Therapeutics stock. In this case, investors may conclude that Esperion Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Esperion Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 8 | 57.16% | 0.0 | 0.024175 | -0.54 |
Esperion Therapeutics Ownership Allocation
Esperion Therapeutics holds a total of 239.06 Million outstanding shares. 30% of Esperion Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Esperion Therapeutics Profitability Analysis
The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 131.9 M.About Esperion Therapeutics Valuation
The stock valuation mechanism determines Esperion Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Esperion Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Esperion Therapeutics. We calculate exposure to Esperion Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Esperion Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 237.3 M | 341.8 M | |
| Pretax Profit Margin | (0.14) | (0.15) | |
| Operating Profit Margin | 0.19 | 0.20 | |
| Net Loss | (0.18) | (0.19) | |
| Gross Profit Margin | 0.91 | 0.89 |
Esperion Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Esperion Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 187.2 M | |
| Forward Price Earnings | 5.9666 |
Esperion Therapeutics Current Valuation Indicators
Esperion Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Esperion Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Esperion Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Esperion Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Esperion Therapeutics' worth.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.